Phase I/II stUdy of ALoCelyvir in patientS with mEtastaticUveal Melanoma (PULSE-UM)

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515032-76-00

Enrollment

Registered

2024-09-06

Start date

2021-11-10

Completion date

2025-09-09

Last updated

2024-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mEtastatic Uveal Melanoma

Brief summary

Efficacy measured by ORR according to the RECIST 1.1 criteria.

Detailed description

-Progression Free Survival (PFS) according to RECIST 1.1 criteria, Overall Survival (OS) rate and Estimated Survival rate at 1, and 2-years

Interventions

DRUGAloCelyvir

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Efficacy measured by ORR according to the RECIST 1.1 criteria.	—

Secondary

Measure	Time frame
-Progression Free Survival (PFS) according to RECIST 1.1 criteria, Overall Survival (OS) rate and Estimated Survival rate at 1, and 2-years	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026